Acceleron Pharma starts Phase 1 ACE-536 trial
Acceleron Pharma, US based discoverer, developer and manufacturer of novel protein therapeutics for orphan diseases and cancer, has started a dose-escalating, multiple-dose Phase 1 to evaluate ACE-536.
ACE-536 is being developed as a treatment of anemia in a global collaboration with Celgene Corporation.
The trial aims to evaluate the tolerability, pharmacodynamics, safety and pharmacokinetics of ACE-536.
Acceleron will receive a $7.5m payment from Celgene for achieving this milestone event.
Acceleron CEO John Knopf said ACE-536 has the potential to make a significant impact on the treatment of anemia, specifically, in diseases such as Myelodysplastic syndromes and beta-thalassemia in which the severe anemia isn't well managed by currently available therapies.
"ACE-536 is our fourth internally discovered, developed and manufactured drug to enter human clinical trials in the past five years," Knopf said.
Related Insight
Suppliers Directory
PFC Pharma Focus - Planning And Conducting Clinical Phase I To IV Studies
The core competency of PFC Pharma Focus AG is the planning and conduction of clinical Phase I to IV studies. It is our aim to handle each project for which we are made responsible with great respect and care: for the patient, for the investigator, for the sponsor and for our collaborators.
Contract Research & Services > Clinical Trials > Suppliers
PDP Couriers - The Global Clinical Trials And Healthcare Specialist
With over 18 years experience PDP is a key specialist Courier company providing global solution-led logistics support services to Contract Research Organizations, Biopharmaceutical Companies and the Healthcare industry.
Contract Research & Services > Clinical Trials > Suppliers
ELPRO - High Quality Temperature and Humidity Dataloggers
ELPRO, The Datalogging Company, is a leading manufacturer of high quality temperature, humidity and other process variables Dataloggers, providing recording and monitoring solutions while observing regulatory compliances (GMP/GLP/FDA 21CFR11).
Contract Research & Services > Clinical Trials > Suppliers
Brainloop - Secure Document Management for Confidential Documents
Brainloop, founded in 2000, is the leading provider of software solutions that enable the secure management of confidential documents across the extended enterprise.
Contract Research & Services > Clinical Trials > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Clinical Trials Intelligence
The Right Source
Published by Multipharma
Contract Research & Services > Clinical Trials > White Papers
Products and Services
Published by PFC Pharma Focus
Contract Research & Services > Clinical Trials > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.